

OPP OFFICIAL RECORD
HEALTH EFFECTS DIVISION
SCIENTIFIC DATA REVIEWS
EPA SERIES 361UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460OFFICE OF
PREVENTION, PESTICIDES, AND
TOXIC SUBSTANCES

TXR No. 0053330

MEMORANDUM

DATE: June 9, 2005

SUBJECT: **Resmethrin**: Quantitative Risk Assessment (Q_1^*) Based On Swiss Crl:CD-1(ICR)BR Mouse and Crl:CD BR Rat Dietary Studies With $3/4$'s Interspecies Scaling Factor

P.C. Code: 097801

TO: William Dykstra, Toxicologist
Reregistration Branch 4
Health Effects Division (7509C)FROM: Lori L. Brunsman, Statistician
Science Information Management Branch
Health Effects Division (7509C)THROUGH: Jess Rowland, Branch Chief
Science Information Management Branch
Health Effects Division (7509C)Summary

The unit risk, Q_1^* (mg/kg/day)⁻¹, of Resmethrin based upon male mouse liver combined adenoma and/or carcinoma tumor rates is 5.621×10^{-2} in human equivalents. The dose levels used from the 105-week dietary study were 0, 300, 600 and 1200 ppm of Resmethrin. The corresponding uncensored tumor rates for the male mouse liver combined tumors were 11/100, 10/50, 14/50 and 18/50, respectively.

Background

On April 13, 2005, the Carcinogenicity Assessment Review Committee recommended that a low dose extrapolation model be applied to the experimental animal tumor data and that

JUN 20 2005

quantifications of risk be estimated for male mouse liver and female rat liver and uterine tumors for Resmethrin. The most potent unit risk will be used for the purpose of lifetime cancer risk assessment by the Agency. In this case, the most potent unit risk, Q_1^* , is that for male mouse liver adenoma and/or carcinoma combined tumor rates at 5.621×10^{-2} in human equivalents.

For the conversion to human equivalents, weights of 0.35 kg for the rat, 0.03 kg for the mouse, 70 kg for humans, molecular weight of 338.4456, and life-span defaults of 105 weeks for both the male mice and female rats. The unit risks, Q_1^* s, for male mice and female rats were obtained by the application of the time-to-tumor Weibull model, which uses uncensored tumor rates. All unit risks have been converted from animals to humans by use of the $3/4$'s scaling factor (QRisk, STATOX for Windows program, Version 4.5, Environ International Corporation, 2005)¹.

It is to be noted that the Q_1^* (mg/kg/day)⁻¹ is an estimate of the upper bound on risk and that, as stated in the EPA Risk Assessment Guidelines, "the true value of the risk is unknown, and may be as low as zero."

Mouse Dose-Response Analysis

A carcinogenicity study in Swiss Crl:CD-1(ICR)BR mice was conducted by Bio-Research Laboratories, Ltd., Senneville, Quebec, Canada, for Roussel UCLAF Corporation, Montvale, New Jersey, and dated January 8, 1992 (Study No. 83754, MRID No. 43052101).

Male mice showed a significant increasing trend in mortality, at $p < 0.01$, with increasing doses of Resmethrin, as well as significant differences in the pair-wise comparisons of the 600 and 1200 ppm dose groups with the controls, both at $p < 0.05$ (**Resmethrin: Qualitative Risk Assessment Based On Crl:CD BR Rat and Swiss Crl:CD-1(ICR)BR Mouse Dietary Studies**, L. Brunsman, 4/12/2005, TXR No. 0053189).

Male mice had a significant increasing trend, and a significant difference in the pair-wise comparison of the 1200 ppm dose group with the controls, for liver adenomas and/or carcinomas combined, both at $p < 0.01$. There were significant differences in the pair-wise comparisons of the 600 ppm dose group with the controls at $p < 0.01$ and of the 300 ppm dose group with the controls at $p < 0.05$, both for liver adenomas and/or carcinomas combined.

Additional Q_1^* Calculations

The unit risk, Q_1^* (mg/kg/day)⁻¹ of Resmethrin based upon female rat liver adenoma and/or

¹See memo - Deriving Q_1^* s Using the Unified Interspecies Scaling Factor, P.A. Fenner-Crisp, Director, HED, 7/1/94.

carcinoma combined tumor rates is 4.502×10^{-3} in human equivalents. The dose levels used from the 105-week dietary study were 0, 250, 1000 and 2500 ppm of Resmethrin. The uncensored tumor rates were 1/65, 0/65, 1/65 and 14/65, respectively.

The unit risk, Q_1^* (mg/kg/day) $^{-1}$, of Resmethrin based upon female rat uterine endometrial stromal polyp rates is 7.673×10^{-3} in human equivalents. The dose levels used from the 105-week dietary study were 0, 250, 1000 and 2500 ppm of Resmethrin. The uncensored tumor rates were 0/65, 1/65, 3/65 and 5/65, respectively.

date: 06/08/2005 at time: 15:51

Risk Assessment : 662

Chemical : RESMETHRIN

Sex : Male

Lesions:

Liver : Adenoma

Liver : Carcinoma

Experimental

Target

| | | |
|----------------------------------------------------------|-----------------------------------------|----------------------------|
| Species: | MOUSE | Human |
| Body Weight: | 0.03000 kg | 70.00 kg |
| Lifespan: | 105 weeks | 70 years |
| Breathing Rate: | 0.34700E-01 l/min | 0.83300 m ³ /hr |
| Food Consumption: | 3.90 g/day | 1400.00 g/day |
| Drinking Rate: | 6.00 ml/day | 2.0 L/day |
| Route: | Food (ppm) | |
| Dosing: Hrs/Day : | 24.0 | |
| Days/Week : | 7.0 | |
| Weeks : | 105.0 | |
| Weeks of Study : | 105.0 | |
| Animal to Human Conversion Method: | Body Weight ³ / ₄ | |
| Conver. Factor 1 (from route units to mg/kg/day) | 0.13000 | |
| Conver. Factor 2 (from mg/kg/day to a-to-h units) | 0.41618 | |
| Conver. Factor 3 (from a-to-h units to target mg/kg/day) | 0.34572 | |

Overall Conversion Factor = 1.87046E-02

Model: Time-to-Tumor Weibull

$$p(d) = 1 - \exp(-q_0 - q_1 * d - q_2 * d^2 - q_3 * d^3) * (t - t_0)^c$$

Maximum Likelihood Estimates of Dose Coefficients

| Untransformed per (ppm) | Human Equivalent per (mg/kg/day) | | |
|---------------------------------------|-------------------------------------|-----------------------|-------------------|
| q(0) = 9.082517855352E-10 | 4.795501089929E-09 | | |
| q(1) = 3.618396887829E-12 | 1.021397424223E-09 | | |
| q(2) = 0.000000000000 | 0.000000000000 | | |
| q(3) = 0.000000000000 | 0.000000000000 | | |
| c = 4.10371155044 | 4.10371155044 | | |
| t0 = 0.000000000000 (weeks) | 0.000000000000 (years) | | |
| Maximum Log-likelihood -106.045190091 | | | |
| Untransformed Dose (ppm) | Human Dose (mg/kg/day) | #Incidental Responses | #Fatal Responses |
| Group | | Observed | Observed #Animals |

| | | | | | |
|---|---------|---------|----|---|-----|
| 1 | 0.00000 | 0.00000 | 11 | 0 | 100 |
| 2 | 300.000 | 5.61139 | 10 | 0 | 50 |
| 3 | 600.000 | 11.2228 | 14 | 0 | 50 |
| 4 | 1200.00 | 22.4456 | 18 | 0 | 50 |

Calculations are based on Extra Risk

Risk calculations at time 105.0 wks (animal) equiv. to 70 yrs (Human)

Unit potency (per mg/kg/day) (Computed for Risk of 1.E-6)

Lower Bound = 8.78473E-03 MLE = 3.81017E-02 Upper Bound (q1*) = 5.62092E-02

95.0% Lower MLE 95.0% Upper

| Extra Risk | Time (yrs) | Bound on Dose (mg/kg/day) | Doses (mg/kg/day) | Bound on Dose (mg/kg/day) |
|------------|------------|---------------------------|-------------------|---------------------------|
|------------|------------|---------------------------|-------------------|---------------------------|

| | | | | |
|----------|----|-------------|-------------|-------------|
| 0.10 | 70 | 1.8744 | 2.7652 | 6.3397 |
| 0.05 | 70 | 0.91254 | 1.3462 | 3.7702 |
| 0.01 | 70 | 0.17880 | 0.26378 | 0.99883 |
| 0.005 | 70 | 8.91765E-02 | 0.13156 | 0.53092 |
| 0.001 | 70 | 1.77996E-02 | 2.62586E-02 | 0.11265 |
| 0.0001 | 70 | 1.77916E-03 | 2.62468E-03 | 1.14315E-02 |
| 1.000E-5 | 70 | 1.77908E-04 | 2.62456E-04 | 1.14781E-03 |
| 1.000E-6 | 70 | 1.77907E-05 | 2.62455E-05 | 1.13834E-04 |

date: 06/08/2005 at time: 15:10

Risk Assessment : 661

Chemical : RESMETHRIN

Sex : Female

Lesions:

Liver : Adenoma

Liver : Carcinoma

| | Experimental | Target |
|-------------------|----------------|----------------------------|
| Species: | RAT | Human |
| Body Weight: | 0.35000 kg | 70.00 kg |
| Lifespan: | 105 weeks | 70 years |
| Breathing Rate: | 0.18050 l/min. | 0.83300 m ³ /hr |
| Food Consumption: | 17.50 g/day | 1400.00 g/day |
| Drinking Rate: | 35.00 ml/day | 2.0 L/day |
| Route: | Food (ppm) | |
| Dosing: Hrs/Day : | 24.0 | |
| Days/Week : | 7.0 | |
| Weeks : | 105.0 | |

Weeks of Study : 105.0

Animal to Human Conversion Method: Body Weight ^{3/4}

Conver. Factor 1 (from route units to mg/kg/day) 5.00000E-02

Conver. Factor 2 (from mg/kg/day to a-to-h units) 0.76916

Conver. Factor 3 (from a-to-h units to target mg/kg/day) 0.34572

Overall Conversion Factor = 1.32957E-02

Model: Time-to-Tumor Weibull

 $p(d) = 1 - \exp(-q_0 - q_1 * d - q_2 * d^2 - q_3 * d^3) * (t - t_0)^c$

Maximum Likelihood Estimates of Dose Coefficients

| Untransformed per (ppm) | Human Equivalent per (mg/kg/day) |
|-----------------------------|-------------------------------------|
| q(0) = 3.127168223873E-14 | 3.189968751236E-13 |
| q(1) = 0.000000000000 | 0.000000000000 |
| q(2) = 0.000000000000 | 0.000000000000 |
| q(3) = 6.688962170637E-23 | 2.903062233427E-16 |
| c = 5.72791170735 | 5.72791170735 |
| t0 = 0.000000000000 (weeks) | 0.000000000000 (years) |

Maximum Log-likelihood -40.7704131760

| Untransformed Dose (ppm) | Human Dose (mg/kg/day) | #Incidental Responses Observed | #Fatal Responses Observed | #Animals |
|-----------------------------|---------------------------|-----------------------------------|------------------------------|----------|
| 1 0.00000 | 0.00000 | 1 | 0 | 65 |
| 2 250.000 | 3.32394 | 0 | 0 | 65 |
| 3 1000.00 | 13.2957 | 1 | 0 | 65 |
| 4 2500.00 | 33.2394 | 14 | 0 | 65 |

Calculations are based on Extra Risk

Risk calculations at time 105.0 wks (animal) equiv. to 70 yrs (Human)

Unit potency (per mg/kg/day) (Computed for Risk of 1.E-6)

Lower Bound = 1.42959E-06 MLE = 2.20701E-06 Upper Bound (q1*) = 4.50199E-03

95.0% Lower MLE 95.0% Upper

| Extra Risk | Time (yrs) | Bound on Dose (mg/kg/day) | Doses (mg/kg/day) | Bound on Dose (mg/kg/day) |
|---------------|---------------|------------------------------|----------------------|------------------------------|
| 0.10 | 70 | 15.096 | 21.400 | 33.038 |
| 0.05 | 70 | 9.8908 | 16.835 | 25.990 |
| 0.01 | 70 | 2.2160 | 9.7781 | 15.096 |
| 0.005 | 70 | 1.1113 | 7.7544 | 11.971 |
| 0.001 | 70 | 0.22222 | 4.5318 | 6.9962 |
| 0.0001 | 70 | 2.22135E-02 | 2.1031 | 3.2469 |
| 1.000E-5 | 70 | 2.22125E-03 | 0.97618 | 1.5071 |
| 1.000E-6 | 70 | 2.22124E-04 | 0.45310 | 0.69950 |

date: 06/09/2005 at time: 14:28

Risk Assessment : 661

Chemical : RESMETHRIN

Sex : Female

Lesions:

Uterus : Endometrial Stromal Polyp

Experimental

Target

| | | |
|----------------------------------------------------------|----------------------------|----------------------------|
| Species: | RAT | Human |
| Body Weight: | 0.35000 kg | 70.00 kg |
| Lifespan: | 105 weeks | 70 years |
| Breathing Rate: | 0.18050 l/min | 0.83300 m ³ /hr |
| Food Consumption: | 17.50 g/day | 1400.00 g/day |
| Drinking Rate: | 35.00 ml/day | 2.0 L/day |
| Route: | Food (ppm) | |
| Dosing: Hrs/Day : | 24.0 | |
| Days/Week : | 7.0 | |
| Weeks : | 105.0 | |
| Weeks of Study : | 105.0 | |
| Animal to Human Conversion Method: | Body Weight ^{3/4} | |
| Conver. Factor 1 (from route units to mg/kg/day) | 5.00000E-02 | |
| Conver. Factor 2 (from mg/kg/day to a-to-h units) | 0.76916 | |
| Conver. Factor 3 (from a-to-h units to target mg/kg/day) | 0.34572 | |

Overall Conversion Factor = 1.32957E-02

Model: Time-to-Tumor Weibull

$$p(d) = 1 - \exp(-q_0 - q_1 * d - q_2 * d^2 - q_3 * d^3) * (t - t_0)^c$$

Maximum Likelihood Estimates of Dose Coefficients

| | Untransformed per (ppm) | Human Equivalent per (mg/kg/day) |
|---------------------------------------|----------------------------|-------------------------------------|
| q(0) = | 0.00000000000 | 0.00000000000 |
| q(1) = | 7.949042242169E-12 | 2.363863502732E-09 |
| q(2) = | 0.00000000000 | 0.00000000000 |
| q(3) = | 0.00000000000 | 0.00000000000 |
| c = | 3.39040177068 | 3.39040177068 |
| t0 = | 0.00000000000 (weeks) | 0.00000000000 (years) |
| Maximum Log-likelihood -34.0419231846 | | |
| Untransformed | Human | #Incidental |
| Dose | Dose | Responses |
| Group (ppm) | (mg/kg/day) | Observed |
| 1 | 0.00000 | 0 |
| 2 | 250.000 | 1 |
| 3 | 1000.00 | 3 |
| 4 | 2500.00 | 5 |

Calculations are based on Extra Risk

Risk calculations at time 105.0 wks (animal) equiv. to 70 yrs (Human)

Unit potency (per mg/kg/day) (Computed for Risk of 1.E-6)

Lower Bound = 8.18138E-06 MLE = 4.25839E-03 Upper Bound (q1*) = 7.67310E-03

95.0% Lower MLE 95.0% Upper

| Extra Risk | Time (yrs) | Bound on Dose (mg/kg/day) | Doses (mg/kg/day) | Bound on Dose (mg/kg/day) |
|------------|------------|---------------------------|-------------------|---------------------------|
| 0.10 | 70 | 13.731 | 24.742 | 63.840 |
| 0.05 | 70 | 6.6848 | 12.045 | 31.080 |
| 0.01 | 70 | 1.3098 | 2.3601 | 11.638 |
| 0.005 | 70 | 0.65326 | 1.1771 | 8.3175 |
| 0.001 | 70 | 0.13039 | 0.23495 | 3.7922 |
| 0.0001 | 70 | 1.30332E-02 | 2.34842E-02 | 1.2150 |
| 1.000E-5 | 70 | 1.30326E-03 | 2.34831E-03 | 0.38594 |
| 1.000E-6 | 70 | 1.30325E-04 | 2.34830E-04 | 0.12223 |



13544

R110054

Chemical: Resmethrin

PC Code: 097801
HED File Code 14000 Risk Reviews
Memo Date: 06/09/2005
File ID: 00000000
Accession Number: 412-05-0096

HED Records Reference Center
06/27/2005